The FDA placed it in 503A Category 2 ("may present significant safety risks") in 2023, effectively barring compounding pharmacies from using it, then removed it from that category in April 2026 after nominators withdrew their submission, without adding it to the approved Category 1 compounding list
Live Happier Important notice about our Peptide Department Peptide Therapy at Revival Clinic is provided through a dedicated Peptide Department under the Revival Clinic umbrella
It can lengthen the growth (anagen) phase of hair, resulting in longer, thicker strands
The four subcutaneous areas that work best are the lower abdomen, the outer thigh, the back of the upper arm, and the flank or love-handle area
The greater concern is chronic accumulation over years of continuous use, which cycling protocols address by providing regular breaks
Seiwerth S, et al